Top Page
Starpharma Holdings Limited
(OTC:SPL)
Starpharma Holdings Limited (SPL) vs. iShares MSCI Australia ETF (EWA)
Starpharma Holdings Limited Business Overview & Revenue Model
Starpharma Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.85M | 4.91M | 8.29M | 2.94M | 4.68M | 1.80M |
| Gross Profit | -3.73M | 3.69M | 7.66M | 1.22M | 1.91M | 539.50K |
| EBITDA | -9.72M | -10.93M | -9.63M | -22.08M | -22.34M | -26.05M |
| Net Income | -9.99M | -9.99M | -8.16M | -15.64M | -16.15M | -19.73M |
Balance Sheet | ||||||
| Total Assets | 25.42M | 25.42M | 36.81M | 52.09M | 66.17M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 15.41M | 15.41M | 23.36M | 35.18M | 49.92M | 60.50M |
| Total Debt | 2.40M | 2.40M | 3.53M | 8.27M | 8.19M | 1.17M |
| Total Liabilities | 6.42M | 6.42M | 8.70M | 17.27M | 17.78M | 10.94M |
| Stockholders Equity | 19.00M | 19.00M | 28.12M | 34.81M | 48.39M | 62.30M |
Cash Flow | ||||||
| Free Cash Flow | -6.80M | -6.80M | -7.07M | -14.15M | -14.00M | -15.05M |
| Operating Cash Flow | -6.76M | -6.76M | -6.98M | -13.53M | -13.16M | -14.81M |
| Investing Cash Flow | -42.00K | -42.00K | -89.00K | -610.00K | -836.00K | -246.00K |
| Financing Cash Flow | -1.13M | -1.13M | -4.75M | -695.00K | 3.23M | 46.30M |
Starpharma Holdings Limited Technical Analysis
Starpharma Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$150.56M | -15.00 | -41.51% | ― | -40.74% | -21.21% | |
50 Neutral | AU$81.92M | -7.63 | -138.54% | ― | ― | 16.61% | |
50 Neutral | AU$88.33M | -9.23 | -49.72% | ― | ― | 10.78% | |
46 Neutral | AU$27.18M | -5.57 | -157.93% | ― | ― | -36.89% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
43 Neutral | AU$115.69M | -19.03 | -90.37% | ― | ― | 26.38% |
Starpharma Holdings Limited Corporate Events
Starpharma Holdings Limited announced a change in the director’s interest, specifically the issuance of 6,525,939 Performance Rights to CEO Cheryl Maley under the SPL Performance Rights Plan. This move, approved by shareholders at the 2024 AGM, increases Maley’s total Performance Rights to 13,487,573, reflecting the company’s commitment to aligning executive incentives with shareholder interests.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has announced the issuance of 16,156,437 unquoted securities under an employee incentive scheme. This move is part of the company’s strategy to motivate and retain key personnel, potentially impacting its operational effectiveness and competitive positioning in the pharmaceutical industry.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried with significant majorities. The successful resolutions, including the re-election of a board director and approval of performance rights, reflect strong shareholder support and are expected to positively impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced significant progress at its Annual General Meeting, highlighting strategic partnerships with Genentech and Radiopharm Theranostics. These partnerships validate Starpharma’s DEP® platform and open new avenues for innovation and revenue, with the Genentech deal alone potentially bringing in up to USD $564 million in milestone payments. The company is focused on maximizing its DEP® platform, accelerating innovation, and building long-term sustainability, with strategic partnerships playing a crucial role in its growth and market expansion.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has announced significant progress in its strategic initiatives during the first quarter of FY26, highlighted by two major partnership agreements. The company signed a collaboration and license agreement with Genentech, a member of the Roche Group, for the development of DEP® cancer therapies, securing an upfront payment of USD $5.5 million and potential milestone payments up to USD $564 million. Additionally, a research and option agreement with Radiopharm Theranostics was established to develop a novel radiotherapy asset, marking Starpharma’s first radiopharmaceutical partnership. These agreements reflect growing industry validation of Starpharma’s DEP® platform, enhancing its commercial traction and positioning within the biotechnology sector. The company also received a $3.7 million R&D tax incentive refund and reported a cash balance of $14.3 million at the end of September 2025. Starpharma remains focused on advancing its DEP® HER2 radiopharmaceuticals program, expanding partnerships, and driving revenue growth through licensing and product sales.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has received an upfront payment of USD $5.5 million from Genentech as part of a recently announced license agreement. This collaboration will utilize Starpharma’s proprietary DEP® platform technology to develop dendrimer-drug conjugates incorporating Genentech medicines for oncology targets. The agreement positions Starpharma to potentially receive up to USD $564 million in development, commercial, and net sales milestones, alongside tiered royalties on global net sales. This partnership enhances Starpharma’s industry positioning by leveraging its advanced dendrimer technology to expand its product offerings and market reach in oncology.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited, a leader in dendrimer technology, presented at the Australian Microcap Investment Conference, highlighting its strategic focus on transforming drug delivery in oncology through its DEP® platform. The company is advancing its pipeline of novel assets, particularly in radiopharmaceuticals, and has secured strategic partnerships with major biotech firms like Genentech and Radiopharm Theranostics. These collaborations underscore the platform’s potential and are expected to expand commercial opportunities significantly. Key developments in the coming year include progressing radiotheranostics to clinical trials, expanding partnerships, and increasing revenue from licensing and product sales.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced a change in the director’s interest, with Robert B. Thomas acquiring 450,000 ordinary shares through an on-market purchase. This transaction increases his direct holding to 950,000 shares, reflecting a significant personal investment in the company, which could signal confidence in the company’s future prospects.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has announced its 2025 Annual General Meeting, scheduled for November 14, 2025, which will be held in a hybrid format allowing both in-person and remote participation. The Board recommends shareholders vote in favor of all resolutions, emphasizing the importance of shareholder engagement and participation in the company’s strategic decisions.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced a change in the director’s interest notice, revealing that Cheryl Maley, a director, has experienced a lapse of 439,752 performance rights due to unmet performance criteria. This adjustment in director’s interests reflects internal performance evaluations and may impact the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical molecule using Starpharma’s DEP® platform. This collaboration marks a significant milestone for both companies, potentially enhancing Radiopharm’s cancer treatment offerings and demonstrating the applicability of Starpharma’s technology in targeted cancer therapies. The agreement includes an exclusive option for Radiopharm to license the developed asset, with significant financial terms tied to successful development and commercialization.
Starpharma has entered into a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary DEP® platform technology. This partnership is a significant milestone for Starpharma, marking its first radiopharmaceutical collaboration and the advancement of its Star Navigator program into a formal research collaboration. The agreement allows Starpharma to receive R&D service and manufacturing fees, with the potential for substantial financial gains through licensing options, success-based milestones, and royalties. This collaboration highlights the potential of dendrimers in radiopharmaceutical drug development and expands Starpharma’s commercial opportunities without impacting its internal development efforts.